You are here
bioMérieux – Second-Quarter 2017 Business Review20 July, 2017
- Good sales dynamic confirmed in second-quarter 2017, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation:
- €1,134 million in sales
- Up 13.3% as reported
- Noticeable performance from the Americas region, led by the success of FilmArray® and by the fast-paced growth of microbiology lines
- Robust growth in the Asia Pacific and Europe – Middle East – Africa regions, buoyed by all of the Group's strategic lines
Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux's strong sales dynamic in first-half 2017 drove organic sales growth of over 11%. In light of this better-than-anticipated performance, we expect to achieve the higher end of our target organic sales growth range for the full year. More detailed information on our financial objectives for 2017 will be given on August 30, when we publish our first-half results."
Marcy l'Étoile (France), July 20, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review for the six months ended June 30, 2017.
Consolidated sales rose to €1,134 million for the first six months of 2017, up from €1,001 million in the same period one year earlier. This represents growth of 13.3% as reported, including a positive currency effect of around €21 million. Organic growth (at constant exchange rates and scope of consolidation) came to 11.3% year-on-year, with FilmArray® accounting for more than half of the increase.
bioMérieux Sweden AB - Hantverksvägen 15 - SE-436 33 Askim, SWEDEN